InvestorsHub Logo
Followers 3
Posts 80
Boards Moderated 0
Alias Born 08/12/2022

Re: None

Friday, 08/19/2022 2:15:03 PM

Friday, August 19, 2022 2:15:03 PM

Post# of 1453
Analyst update for ONCT

After Oncternal reported interim results from its ongoing Phase 1/2 CIRLL Study that Northland analyst Carl Byress said enforce the potential for the combination of Zilovertamab plus Ibrutinib for treating relapsed/ refractory mantle cell lymphoma, he argued that the updated interim data for the combination should serve as a catalysts doe shares as they are clearly supporting the registrational Phase 3 studies intitiating in Q3 of this year. He also noted that relapsed/ refractory mantle cell lymphoma patients achieve progression free survival or PFS which he sees bodes well for Zilvertamab as a major breakthrough byrnes has an outperform rating and a $15.00 price target on Oncternal shares.

$ONCT
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCT News